Dare Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO(TM) (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

Source :: GlobeNewswire. October 16, 2023
Publication Year :: 2023
Abstract: SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) [...]

Subjects :: Clindamycin -- Licensing agreements
Biotechnology industry -- Licensing agreements
Governmental investigations
Phosphates -- Licensing agreements
Company licensing agreement
Banking, finance and accounting industries
Business

Tools